This episode delves into the real-world consequences of non-compliance, focusing on the FDA Form 483. We will cover the implications and impact of these observations. We analyze a decade of FDA Form 483 observations in the "Drugs" category. Examine recurring issues identified by the FDA, such as problems with documentation, process validation, facility controls, equipment maintenance, and training.

We discuss how these findings impact not only manufacturers and CDMOs but also public health. Explore best practices for addressing 483 observations. Learn about the importance of implementing effective corrective and preventive actions (CAPA) to prevent recurrence. Discover how a proactive approach to quality management can minimize the risk of receiving a 483 and ensure sustained compliance.